GeneFerm Biotechnology Co Ltd Cash Flow Conversion Efficiency
GeneFerm Biotechnology Co Ltd cash flow conversion efficiency. Based on the latest financial reports, GeneFerm Biotechnology Co Ltd (1796) has a cash flow conversion efficiency ratio of 0.002x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$1.45 Million ≈ $45.65K USD) by net assets (NT$794.03 Million ≈ $25.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of GeneFerm Biotechnology Co Ltd (2017–2024)
Cash flow conversion efficiency of GeneFerm Biotechnology Co Ltd from 2017 to 2024. This chart illustrates how GeneFerm Biotechnology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View GeneFerm Biotechnology Co Ltd stock price for real-time trading data and today's change.
GeneFerm Biotechnology Co Ltd Cash Flow Conversion Ratio Explained
GeneFerm Biotechnology Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
GeneFerm Biotechnology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GeneFerm Biotechnology Co Ltd ranked by their cash flow conversion efficiency. Also see 1796 stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Taylor Wimpey PLC
LSE:TW
|
-0.001x |
|
Sumi Indo Kabel Tbk
JK:IKBI
|
0.195x |
|
Very Good Tour Co. Ltd
KQ:094850
|
-0.015x |
|
Abico FS Co Ltd
TWO:8071
|
0.045x |
|
Vardhman Acrylics Limited
NSE:VARDHACRLC
|
-0.045x |
|
Mr Bricolage
PA:ALMRB
|
-0.020x |
|
Co2 Capsol AS
OL:CAPSL
|
-0.288x |
|
Veru Inc
NASDAQ:VERU
|
-0.166x |
Annual Cash Flow Conversion Efficiency for GeneFerm Biotechnology Co Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of GeneFerm Biotechnology Co Ltd from 2017 to 2024. Review GeneFerm Biotechnology Co Ltd (1796) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$788.18 Million ≈ $24.83 Million |
NT$8.09 Million ≈ $254.88K |
0.010x | -95.18% |
| 2023-12-31 | NT$892.84 Million ≈ $28.13 Million |
NT$190.31 Million ≈ $6.00 Million |
0.213x | +44.64% |
| 2022-12-31 | NT$830.77 Million ≈ $26.17 Million |
NT$122.43 Million ≈ $3.86 Million |
0.147x | -1.82% |
| 2021-12-31 | NT$747.66 Million ≈ $23.56 Million |
NT$112.23 Million ≈ $3.54 Million |
0.150x | +5.41% |
| 2020-12-31 | NT$396.19 Million ≈ $12.48 Million |
NT$56.42 Million ≈ $1.78 Million |
0.142x | +825.46% |
| 2019-12-31 | NT$954.50 Million ≈ $30.07 Million |
NT$14.69 Million ≈ $462.72K |
0.015x | -84.79% |
| 2018-12-31 | NT$416.51 Million ≈ $13.12 Million |
NT$42.14 Million ≈ $1.33 Million |
0.101x | -47.83% |
| 2017-12-31 | NT$314.95 Million ≈ $9.92 Million |
NT$61.08 Million ≈ $1.92 Million |
0.194x | -- |
About GeneFerm Biotechnology Co Ltd
GeneFerm Biotechnology Co., Ltd. develops, manufactures, and sells fermented health products in Taiwan and internationally. The company offers microbial fermentation products, including fungi, bacteria, lactic acid bacteria, yeast, algae, etc.; bio fermented ingredients, such as nattomena, natto fermented powder, red yeast rice fermented powder, antrodia cinnamomea mycelia powder, cordyceps, reis… Read more